Prevalence and long-term outcomes of patients with life-limiting illness admitted to intensive care units in Australia and New Zealand.

End-of-life Intensive care Life-limiting illness Long-term outcomes

Journal

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
ISSN: 1441-2772
Titre abrégé: Crit Care Resusc
Pays: Netherlands
ID NLM: 100888170

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 07 12 2023
revised: 14 02 2024
accepted: 23 02 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: epublish

Résumé

Determine the prevalence and outcomes of patients with life-limiting illness (LLI) admitted to Australian and New Zealand Intensive Care Units (ICUs). Retrospective registry-linked observational cohort study of all adults admitted to Australian and New Zealand ICUs from 1st January 2018 until 31st December 2020 (New Zealand) and 31st March 2022 (Australia), recorded in the Australian and New Zealand Intensive Care Society Adult Patient Database. The primary outcome was 1-year mortality. Secondary outcomes included ICU and hospital mortality, ICU and hospital length of stay, and 4-year survival. A total of 566,260 patients were included, of whom 129,613 (22.9%) had one or more LLI. Mortality at one year was 28.1% in those with LLI and 10.4% in those without LLI (p < 0.001). Mortality in intensive care (6.8% v 3.4%, p < 0.001), hospital (11.8% v 5.0%, p < 0.001), and at two (36.6% v 14.1%, p < 0.001), three (43.7% v 17.7%, p < 0.001) and four (55.6% v 24.5%, p < 0.001) years were all higher in the cohort of patients with LLI. Patients with LLI had a longer ICU (1.9 [0.9, 3.7] v 1.6 [0.9, 2.9] days, p < 0.001) and hospital length of stay (8.8 [49,16.0] v 7.2 [3.9, 12.9] days, p < 0.001), and were more commonly readmitted to ICU during the same hospitalisation than patients without LLI (5.2% v 3.7%, p < 0.001). After multivariate analysis the LLI with the strongest adverse effect on survival was frailty (HR 2.08, 95% CI 2.03 to 2.12, p < 0.001), followed by the presence of metastatic cancer (HR 1.97, 95% CI 1.92 to 2.02, p < 0.001), and chronic liver disease (HR 1.65, 95% CI 1.65 to 1.71, p < 0.001). Patients with LLI account for almost a quarter of ICU admissions in Australia and New Zealand, require prolonged ICU and hospital care, and have high mortality in subsequent years. This knowledge should be used to identify this vulnerable cohort of patients, and to ensure that treatment is aligned to each patient's values and realistic goals.

Identifiants

pubmed: 39072231
doi: 10.1016/j.ccrj.2024.02.001
pii: S1441-2772(24)00004-8
pmc: PMC11282342
doi:

Types de publication

Journal Article

Langues

eng

Pagination

116-122

Informations de copyright

Crown Copyright © 2024 Published by Elsevier B.V. on behalf of College of Intensive Care Medicine of Australia and New Zealand.

Auteurs

Kate Wagner (K)

Cabrini Hospital, Malvern, VIC, Australia.

Neil Orford (N)

University Hospital Geelong, Barwon Health, Geelong, VIC, Australia.
School of Medicine, Deakin University, Geelong, VIC, Australia.
Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventative Medicine (SPHPM), Monash University, Melbourne, VIC, Australia.
Department of Critical Care, University of Melbourne, Melbourne, VIC, Australia.

Sharyn Milnes (S)

University Hospital Geelong, Barwon Health, Geelong, VIC, Australia.
School of Medicine, Deakin University, Geelong, VIC, Australia.

Paul Secombe (P)

Alice Springs Hospital, Alice Springs, NT, Australia.
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.

Steve Philpot (S)

Cabrini Hospital, Malvern, VIC, Australia.
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
Department of Intensive Care, Alfred Health, Commercial Road, Prahran 3004, VIC, Australia.

David Pilcher (D)

Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventative Medicine (SPHPM), Monash University, Melbourne, VIC, Australia.
Department of Intensive Care, Alfred Health, Commercial Road, Prahran 3004, VIC, Australia.
Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resources Evaluation, 101 High Street, Prahran, VIC 3004, Australia.

Classifications MeSH